We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

173 hedge funds and large institutions have $1.82B invested in Edgewise Therapeutics in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 58 increasing their positions, 62 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $3.84M | Put options by funds: $2.02M

17% more capital invested

Capital invested by funds: $1.56B → $1.82B (+$259M)

6% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 62

3% less funds holding

Funds holding: 178173 (-5)

6.59% less ownership

Funds ownership: 112.87%106.28% (-6.6%)

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

25% less funds holding in top 10

Funds holding in top 10: 86 (-2)

Holders
173
Holders Change
-5
Holders Change %
-2.81%
% of All Funds
2.27%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
18
Increased
58
Reduced
62
Closed
23
Calls
$3.84M
Puts
$2.02M
Net Calls
+$1.82M
Net Calls Change
+$2.2M
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$252M
RCM
2
RA Capital Management
Massachusetts
$169M +$7.46M +525,804 +5%
BBA
3
Baker Bros. Advisors
New York
$119M
BlackRock
4
BlackRock
New York
$103M -$6.09M -429,559 -6%
PBA
5
Paradigm Biocapital Advisors
New York
$100M +$394K +27,787 +0.5%
NHAS
6
Novo Holdings A/S
Denmark
$86.8M
B
7
Braidwell
Connecticut
$84.5M
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$80.8M -$7.43M -524,018 -10%
Vanguard Group
9
Vanguard Group
Pennsylvania
$77.9M -$533K -37,559 -0.8%
CAM
10
Cormorant Asset Management
Massachusetts
$65M -$3.43M -241,992 -6%
SL
11
Siren LLC
Connecticut
$63.2M +$10.5M +736,801 +23%
PA
12
Perceptive Advisors
New York
$61.6M -$12M -844,055 -18%
BG
13
Bellevue Group
Switzerland
$45M
DCM
14
Driehaus Capital Management
Illinois
$36.1M +$1.79M +126,504 +6%
MB
15
MPM BioImpact
Massachusetts
$27.9M
Geode Capital Management
16
Geode Capital Management
Massachusetts
$27.9M -$1.13M -79,574 -4%
State Street
17
State Street
Massachusetts
$27.6M -$1.16M -81,592 -5%
IHAM
18
Integral Health Asset Management
New York
$24.3M +$7.09M +500,000 +50%
FLAM
19
First Light Asset Management
Minnesota
$23M -$4.24M -299,025 -17%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$19.2M +$1.9M +134,200 +13%
American Century Companies
21
American Century Companies
Missouri
$17.8M +$4.43M +312,307 +40%
NLVP
22
New Leaf Venture Partners
New York
$16.7M
Morgan Stanley
23
Morgan Stanley
New York
$14.1M +$2.01M +141,964 +20%
DM
24
Deerfield Management
New York
$12.4M -$18.5M -1,301,626 -63%
Millennium Management
25
Millennium Management
New York
$11.8M -$2.79M -196,540 -21%

EWTX Hedge Fund Activity: Q3 2025 in Review

173 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q3 2025, worth a combined $1.82B — up 17% from $1.56B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of EWTX and 18 opened new positions — a net loss of 5 holders — while 62 trimmed existing stakes and 58 added.

The largest buyer was Siren LLC, adding an estimated $10.5M. The largest seller was Deerfield Management, cutting an estimated $18.5M.

  • 173 institutional investors held Edgewise Therapeutics (EWTX) as of Q3 2025, down from 178 in Q2 2025.
  • Funds reported $1.82B of Edgewise Therapeutics stock for Q3 2025, up 17% quarter-over-quarter.
  • 18 funds opened new Edgewise Therapeutics positions in Q3 2025 and 23 closed out, a net change of -5 holders.
  • The largest Edgewise Therapeutics buyer in Q3 2025 was Siren LLC, an estimated $10.5M added.
  • The largest Edgewise Therapeutics seller in Q3 2025 was Deerfield Management, an estimated $18.5M sold.

Based on aggregated 13F filings for Q3 2025.